EGFR and non-small cell lung carcinoma: Similar results were achieved in the following KEYNOTE-010 [145], OAK [36], and PACIFIC trials [146], which showed that previously treated NSCLC patients with wild-type EGFR derived a survival benefit from ICIs, but those with an EGFR mutation did not.